Navigation Links
Actos Lawsuit News: Bernstein Liebhard LLP Notes Latest Scheduling Order in Actos Bladder Cancer Litigation
Date:2/24/2013

New York, New York (PRWEB) February 24, 2013

Actos lawsuits continue to move forward in the federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana. According to a Scheduling Order dated February 19, 2013, the Court has established a Pilot Bellwether Program, which sets up a stream-lined selection process for a minimum of two Pilot Bellwether trials. The Order stipulates that the litigation’s first Pilot Bellwether trial will begin on January 27, 2014, while the second will commence on April 14, 2014. Attorneys for both sides have been directed to nominate five Actos lawsuits each to participate in the Pilot Bellwether Discovery Pool by April 1, 2013.* (In re: Actos Product Liability Litigation, MDL No. 2299)

“The bellwether trials will provide valuable insight into how juries might weigh similar Actos claims. We look forward to this process getting underway,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to individuals who may have been harmed by the medication.

Actos Bladder Cancer Lawsuits
Actos, known generically as pioglitazone, is approved as a treatment for type 2 diabetes. The U.S. Food & Drug Administration (FDA) ordered Takeda Pharmaceuticals to add new warnings to the Actos label in June 2011, after a study found that long-term use of the drug increased the risk for bladder cancer.* Since then, hundreds of people have filed Actos bladder cancer lawsuits alleging long-term use of the drug caused them to develop the disease.

The nation’s first trial involving an Actos bladder cancer lawsuit is now underway in Los Angeles Superior Court. According to a recent report from Bloomberg.com, court filings in that case show Takeda Pharmaceuticals secretly surveyed a dozen doctors in 2003 to see if they would use a diabetes drug with their patients that carried a warning about the potential for bladder cancer. Plaintiff’s attorneys assert the survey found that “a bladder cancer warning would destroy the sales of Takeda’s most important drug.”**(Cooper v. Takeda Pharmaceuticals America, Inc., CGC-12-518535, California Superior Court (Los Angeles))

After the FDA mandated the Actos label change in June 2011, a number of additional studies confirmed the link between long-term use of the drug and bladder cancer. Most recently, a study published in the British Diabetic Association journal, “Diabetic Medicine,” found that the risk of bladder cancer was significantly higher in patients using Actos compared with control groups.****

Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com/. For additional information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.

*lawd.uscourts.gov/sites/default/files/UPLOADS/11-md-2299.021913.Scheduling.Order.PBP.pdf
** fda.gov/drugs/drugsafety/ucm259150.htm
***bloomberg.com/news/2013-02-15/takeda-worried-about-actos-s-cancer-link-filing-shows.html
**** ncbi.nlm.nih.gov/pubmed/23350856

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb10461720.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
2. Victim’s Rights to Recover for Actos Bladder Cancer Could Expire Soon
3. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
4. Researchers Offer Explanation for Actos Bladder Cancer Risk
5. New Lawsuit alleges Actos caused Bladder Cancer
6. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
7. US Drug Watchdog Now Urges Users Of The Diabetes Drug Called Actos To Call The Johnson Law Group if They Have Developed Bladder Cancer-Time Is Of The Essence
8. US Drug Watchdog Now Urges Any US Citizen Who Used the Diabetes Drug Called Actos and Then Developed Bladder Cancer To Contact The Johnson Law Group For A Legal Review
9. US Drug Watchdog Now Urges Loved Ones Of A Diabetic Who Died From Bladder Cancer Who Had Used The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
10. US Drug Watchdog Now Expands Their Efforts to Educate Diabetics About the Diabetes Drug Actos and Bladder Cancer, with the Suggestion Victims Call the Johnson Law Group
11. US Drug Watchdog Now Urges Any Diabetic Who Used the Diabetes Drug Actos and Now Have Been Diagnosed with Bladder Cancer to Call The Johnson Law Group-ASAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... , ... ODH, Inc.™ announced today it will exhibit and speak at ... Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present ... population health management. , ODH will also have an exhibit booth where attendees may ...
(Date:2/25/2017)... ... 2017 , ... FCPX users now have the ability to sharpen a desired ... Color users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical ... tools users can visually see the color range effected with ease all within ...
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – ... Private has initiated a second print-run of its lavish luxury travel coffee table book. ... open, weighs in at more than six kilos, retails at EUR 1,000 per copy ...
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of ... critically important that we all are aware of our options and are empowered ... to announce the launch of its newest edition of "Vision and Hearing" in ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... February 24, 2017 Following receiving ... Israel , s AMAR is a major ... 250 M w ound care market in ... BST for inclusion in the National Health Basket ...   E-QURE Corp. (OTCQB: EQUR), a leader ...
(Date:2/24/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... present at the Cowen and Company 37 th ... Place on Tuesday, March 7, 2017 at 11:20 a.m. ... the presentation can be accessed at http://wsw.com/webcast/cowen38/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research and ... and Strategies - 2016" report to their offering. ... The latest research Hemophilia Drugs Price Analysis ... global Hemophilia market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Hemophilia market? ...
Breaking Medicine Technology: